The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Real-world outcomes of ide-cel in heavily pre-treated R/R MM
Surbhi Sidana, MD, Stanford University, Stanford, CA, discusses the real-world outcomes of over 800 patients with relapsed/refractory (R/R) multiple myeloma who have been treated with the CAR T-cell therapy idecabtagene vicleucel (ide-cel). These patients were heavily pre-treated (a median of seven prior lines of therapy) and many had high-risk cytogenetics which would have made them ineligible for the KarMMa-3 clinical trial (NCT03651128). With a median follow-up of around 12 months, safety and efficacy outcomes have been found to be comparable to those observed in KarMMa-3. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Magenta Therapeutics, BMS, Janssen, Sanofi, Oncopeptides, Takeda, Pfizer
Research Funding: Magenta Therapeutics, BMS, Allogene, Janssen, Novartis
